• 18% increase in total revenue to $36.9M
• 30% decrease in net loss to $23.8M
• Continued investment in R&D, notably intangible assets
• Focus on profitability and cash flow break-even in 2026

AVITA Medical Inc. (AVH.ASX) has released its financial results for the first half of 2025, highlighting a strong performance with an 18% increase in total revenue to $36.9 million and a 30% decrease in net loss to $23.8 million compared to the same period in 2024. The company's other income also grew by 42% to $1.7 million. The results reflect AVITA's continued investment in research and development, notably an increase in intangible assets, as well as the company's growth-stage as commercial activities scale up. The increase in working capital liabilities supports this growth. AVITA is focused on profitability and aims to achieve cash flow break-even in 2026. Additional details and commentary on these results are provided in the attached Form 10-Q for the three and six months ended June 30, 2025.

AVITA is focused on profitability and aims to achieve cash flow break-even in 2026 as the company continues to scale up its commercial activities.